Evidence map›Paper›PMID 35975699›Full record

ReviewJournal of surgical oncology2022

A review of hepatic epithelioid hemangioendothelioma-Analyzing patient characteristics and treatment strategies.

Pranay S Ajay, Vasileios Tsagkalidis, Anthony Casabianca, Paul R Burchard, Alexa D Melucci, Alexander Chacon, Subir Goyal, Jeffrey M Switchenko, David A Kooby, Darren R Carpizo and 1 more

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of surgical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Pranay S AjayDivision of Surgical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-9292-8345
Vasileios TsagkalidisDepartment of Surgery, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
Anthony CasabiancaDepartment of Surgery, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
Paul R BurchardDepartment of Surgery, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.ORCID http://orcid.org/0000-0001-7370-5608
Alexa D MelucciDepartment of Surgery, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
Alexander ChaconDepartment of Surgery, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
Subir GoyalDepartment of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
Jeffrey M SwitchenkoDepartment of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
David A KoobyDivision of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID http://orcid.org/0000-0001-8694-0455
Darren R CarpizoDivision of Surgical Oncology, Wilmot Caner Center, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
Mihir M ShahDivision of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-4665-5534
University of Rochester · USEmory University · US

Funding

Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5M
Biostatistics Shared Resource of Winship Cancer Institute of Emory University and NIH/NCI P30CA138292NCI NIH HHS P30 CA138292
6 · The paper itself

Abstract

backgroundHepatic epithelioid hemangioendothelioma (HEH) is a rare vascular tumor of unknown etiology and unpredictable natural history. To date, no large-scale studies have been published evaluating this disease due to its rare occurrence.

methodsThe National Cancer Database was reviewed between 2004 and 2016 to identify patients with HEH. Univariate analysis with overall survival (OS) was performed by Cox proportional hazards model. Kaplan-Meier method was used to create OS curves and compared using the log-rank test.

resultsWe identified 229 patients with HEH. The majority of patients were female (61.1%), white (84.3%), and had a Charlson-Deyo score of 0 (75%). Chemotherapeutic intervention was seen in 26% of the patients while 33% received surgical intervention in the form of wedge/segmental liver resection (n = 27), hepatectomy lobectomy/extended lobectomy (n = 18), and liver transplant (n = 22). Five-year survival in surgical patients was 90.5%, 66.5% and 81%, respectively (p = 0.485). Age greater than 55 years (hazard ratio [HR], 2.78; p < 0.001), Asian ethnicity compared to white (HR, 2.84; p = 0.012), and a higher Charlson-Deyo score (score 1: HR, 2.28; p < 0.001 and score ≥2: HR, 2.76; p = 0.011) were associated with worse OS.

conclusionTreatment for HEH remains variable with only a third of the patients undergoing surgery. International collaboration is necessary to determine the optimal treatment for this rare disease.

Indexed as

Hemangioendothelioma, EpithelioidLiver NeoplasmsLiver TransplantationFemaleHepatectomyHumansMaleMiddle AgedProportional Hazards Modelsepithelioid hemangioendotheliomaHEHHEHE

Identifiers

PMID35975699
PMCPMC9836828
OpenAlexW4292322185

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.